Percutaneous pulmonary valve implantation and surgical valve replacement in patients with right ventricular outflow tract dysfunction - a complementary treatment concept by Dilber, Daniel et al.
  
    
 
Središnja medicinska knjižnica 
 
 
 
 
Dilber D., Hörer J., Malčić I., Hess J., Ewert P., Eicken A. (2013) 
Percutaneous pulmonary valve implantation and surgical valve 
replacement in patients with right ventricular outflow tract 
dysfunction--a complementary treatment concept. International 
Journal of Cardiology, 169(1). pp. e3-5. ISSN 0167-5273 
 
http://www.elsevier.com/locate/issn/01675273 
 
http://www.sciencedirect.com/science/journal/01675273 
 
http://dx.doi.org/10.1016/j.ijcard.2013.08.122 
 
 
 
 
http://medlib.mef.hr/2035 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 
Percutaneous pulmonary valve implantation and surgical valve replacement in 
patients with right ventricular outflow tract dysfunction - A complementary 
treatment concept 
 
Daniel Dilber
1
, Jürgen Hörer
3
,Ivan Malcic
1
, John Hess
2
, Peter Ewert
2
, Andreas 
Eicken
2 
 
 
1
Department of Pediatric Cardiology, University Hospital Zagreb at the Medical 
School of Zagreb, Kispaticeva 12, 10 000 Zagreb, Croatia     
2
Department of Pediatric Cardiology and Congenital Heart Disease, Deutsches 
Herzzentrum München, Technische Universität München, Germany 
3
Department of Cardiothoracic Surgery, Deutsches Herzzentrum München, 
Technische Universität München, Germany 
 
 
 
 
 
 
 
 
 
 
 
Corresponding author: 
Andreas Eicken MD 
Department of Pediatric Cardiology and Congenital Heart Disease  
Deutsches Herzzentrum München 
Technische Universität München 
Lazarettstr. 36 
80636 München 
eicken@dhm.mhn.de 
 
 Today surgical pulmonary valve replacement (SPVR) (1) or percutaneous 
pulmonary valve implantation (PPVI) (2) are the treatment options for right 
ventricular outflow tract (RVOT) dysfunction. The aim of this retrospective study 
was to evaluate results of SPVR and PPVI in a single centre. 
Retrospective analysis of 109 consecutive patients who were scheduled for PPVI 
(53) or SPVR (56) between 05/2006 and 11/2010 at the German Heart Centre 
Munich. The median age at intervention was 20.2 years (8-65y) Both groups did not 
differ in age and gender. The median number of previous surgical procedures was 
significantly higher in the PPVI group (2 vs 3 procedures, respectively)(Table 1). 
The indication for treatment (SPVR/PPVI) was assessed according to current 
recommendations (3,4). Patients with prevailing stenosis and a RVOT diamter < 22 
mm were treated with a Medtronic Melody® valve  and patients with larger outflow 
tracts, usually presenting severe pulmonary regurgitation, were treated surgically. 
All patients received a transthoracic echocardiographical examination (5) before the 
intervention, at hospital discharge and at the latest follow-up examination. For 
calculation of RVOT obstruction the mean Doppler gradients were used. Wilcoxon 
rank sum tests were used to assess differences between the PPVI and surgical group.  
The median peak Doppler velocity across the RVOT was significantly higher before 
PPVI than before SPVR 4.1 m/s (1.7 – 5.1 ) vs 2.9 (1.3 – 5.7) (p<0.001) indicating 
that stenosis was the leading lesion in this group of patients. The peak Doppler flow 
velocity in the PPVI group decreased significantly from a median value of 4.1 m/s 
(1.7 – 5.1) to 2.7 (1.8 – 4.3) (Figure 1; p < 0.0001) at the latest echocardiographic 
examination. In the SPVR group the peak Doppler flow velocity decreased 
significantly from a median value of 2.9 m/s (1.3 – 5.7) to 2.1 (0.8 – 4.0)(p < 
0.0001; Figure 1). Pulmonary regurgitation was more prominent in the surgical 
group.  In analogy to the results in term of stenosis, the PPVI patients with lower 
grades of pulmonary regurgitation before the procedure had significantly lower 
grades of pulmonary regurgitation after the procedure (p<0.001, Figure 2). The 
median follow-up period was similar in both groups. Following PPVI, one patient 
developed endocarditis (S.aureus) six months after PPVI. The Melody® valve was 
replaced by a homograft. In the surgical group, two patients with severe recurrent 
pulmonary regurgitation needed a PPVI two and 24 months after surgery, 
respectively. Another patient underwent sternum re-fixation two years after surgery. 
The median hospital-stay after PPVI was significantly shorter after PPVI than after 
SPVR (2 days [1-26] vs 17 [9-56] days; p<0.001). Early complications were 
significantly more frequent in the surgical group (21/56 ;38% vs 2/53;4%; p<0.001). 
Complications after surgery were: urgent re-operation because of bleeding n = 2, 
pacemaker implantation (AV-block III) n = 1, seizures n = 1, fever of unkown origin 
n = 13, and arrhythmia n = 4. After PPVI one patient was febrile, one had transient 
atrioventricular conduction block. To our knowledge this is the first description of 
surgical valve replacement and PPVI for patients with RVOT dysfunction as a 
complementary treatment concept. Based on the individual morphology our 
interdisciplinary approach offered the adequate treatment. Patients, who were 
eligible for PPVI benefited from shorter hospitalization and fewer periprocedural 
complications. Following hospital discharge patients after PPVI can go back to their 
usual daily activities which is not possible after an open heart operation. In this 
instance some form of physical rehabilitation often is indicated, especially in adults. 
Hence, patients experience a significant advantage, if treated by PPVI. The most 
frequent complication after a cardiac operation in our cohort was fever of unknown 
origin, which only occurred once after PPVI. Fever is a very common complication 
after open heart surgery (10) especially if biological conduits are employed. Some 
investigators tried to attribute this to the influence of HLA mismatch of the 
homografts (11). In absence of bacterial infection the post operative course in 
patients with fever of unknown origin usually is benign, at most the hospital stay is 
prolonged. Only one patient after PPVI had fever of unknown origin. However, one 
percutaneously implanted Melody® valve had to be exchanged due to endocarditis 6 
months after PPVI. Bacterial endocarditis of a biological valve is a severe 
complication. Since it occurred as late as six months after PPVI, an association with 
the implant procedure is not probable. Prosthetic valve endocarditis is a severe form 
of infectitive endocarditis. It occurs in 1 – 6% of patients with artificial valves and 
equally affects bioprosthetic and mechanical valves (12). Further long term studies 
are needed to assess the real incidence of bacterial endocarditis after PPVI. A 
comparative long-term study (PPVI vs surgery) would be very helpful to address this 
issue. The other complications after surgery were two early re-operations for 
bleeding, one pacemaker implantation and one patient developed cerebral seizures 
without permanent residuals. Four patients had arrhythmia which led to transient 
medical treatment in the surgical group. One transient complete AV- block occurred 
in the PPVI-group during the intervention, probably due to the stiff delivery system. 
However, the patient was discharged home in sinus rhythm without a permanent 
pacemaker after three weeks und continues to be in sinus rhythm until today. The 
leading cardiac lesion in patients preceding PPVI was stenosis, whereas pulmonary 
regurgitation was prevailing in the surgical collective. These characteristics were 
still present at the latest follow-up examination showing a tendency for higher 
residual gradients in the PPVI group compared to more significant pulmonary 
regurgitation in the surgical collective. This made the proper interpretation of the 
haemodynamic results of the study impossible. Until today, only mid-term follow-up 
results are available for patients after PPVI. Longer follow-up is needed to assess 
longevity of the percutaneous approach in comparison to surgery.  In conclusion 
patients presenting with RVOT dysfunction can be treated effectively using a 
complementary treatment concept including SPVR and PPVI. The key for an 
optimal treatment is an individual decision making by surgeons and 
interventionalists. Patients, who are eligible for PPVI benefit from shorter 
hospitalization and lower complication rates. 
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Table 1. Patient characteristics previous to RVOT surgery/percutaneous pulmonary valve 
procedure. 
Parameter Surgery Percutaneous pulmonary valve implantation p 
Number of patients 56 53  
Age at procedure 
in years 19.1 (8–65) 22.8 (9.9–52.1) 0.173 
Sex Female 27; male 29 Female 22; male 31 0.305 
Diagnosis TOF/PA, 42; TAC, 2; TGA, 1; AoS, 1, other, 10 
TOF/PA, 29; TAC, 11; TGA, 4; AoS, 
4, other, 5  
RVOT 
characteristics 
Homograft, 52; Hancock, 3; 
Carpentier-Edwards, 1 
Homograft, 48; Hancock 2; Shelhigh 
1; native 3  
Extracardiac 
anomalies 
22q11, 8; AIDS, 1; 
esophageal atresia, 1 
Trisomy 21, 1; 22q11, 3; severe 
mental retardation, 3; 8q deletion, 1  
Previous 
procedures 2 (1–6) 3 (1–5) < 0.001 
Numeric variables are reported as in median (range).p-Value from a Wilcoxon rank sum test 
for age and procedures, Fisher exact test for sex. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
 
Fig. 1. Peak Doppler velocity across the right ventricular outflow tract at base line and at the latest follow-up 
echocardiographic examination: The median peak Doppler velocity was significantly higher before PPVI vs surgery 
(p < 0.0001). In both collectives the gradient was reduced significantly by the intervention/operation (p < 0.0001). 
 
 
 
 
 
 
 
 
 Fig. 2. Pulmonary regurgitation graded by echocardiography at base line and at the latest follow-up echocardiographic 
examination: More than 50% of the patients before surgery had severe pulmonary regurgitation which was improved 
significantly. However, at the latest follow-up 3 patients remained with significant pulmonary regurgitation. None of the 
patients after PPVI had severe pulmonary regurgitation at the latest follow-up examination. 
 
 
 
 
